Patents by Inventor Kwon Yon Musick

Kwon Yon Musick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UDP glycosyltransferase inhibitors and methods of use
    Patent number: 11098056
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: August 24, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Sungtaek Lim, Robert H. Barker, Jr., Mary A. Cromwell, Elina Makino, Bradford Hirth, John Jiang, Sachin Maniar, Mark Munson, Yong-Mi Choi, Sukanthini Thurairatnam, Kwon Yon Musick, James Pribish, Michael Angelastro
  • UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE
    Publication number: 20200102324
    Abstract: Described herein is a compound of Formula (I), and pharmaceutically acceptable salts thereof. Also described herein are compositions and the use of such compositions in methods of treating a variety of diseases and conditions, in particular Krabbe's Disease (KD) and Metachromatic leukodystrophy (MLD).
    Type: Application
    Filed: October 1, 2019
    Publication date: April 2, 2020
    Inventors: Sungtaek LIM, Robert H. BARKER, JR., Mary A. CROMWELL, Elina MAKINO, Bradford HIRTH, John JIANG, Sachin MANIAR, Mark MUNSON, Yong-Mi CHOI, Sukanthini THURAIRATNAM, Kwon Yon MUSICK, James PRIBISH, Michael ANGELASTRO
  • SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
    Publication number: 20120202795
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Philip M. WEINTRAUB, Paul R. EASTWOOD, Shujaath MEHDI, David W. STEFANY, Kwon Yon MUSICK, Neil MOORCROFT, Sungtaek LIM, John Z. JIANG, Hartmut RUTTEN, Stefan PEUKERT, Uwe SCHWAHN
  • Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)
    Patent number: 8173682
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: May 8, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Philip M. Weintraub, Paul R. Eastwood, Shujaath Mehdi, David W. Stefany, Kwon Yon Musick, Neil Moorcroft, Sungtaek Lim, John Z. Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn
  • Substituted AZA-indoles as inhibitors of poly(ADP-ribose) polymerase (PARP)
    Patent number: 8008491
    Abstract: The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: August 30, 2011
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: John Ziqi Jiang, Jack Roger Koehl, Shujaath Mehdi, Neil Moorcroft, Kwon Yon Musick, Philip Marvin Weintraub, Paul Robert Eastwood
  • Thienopyrazoles
    Patent number: 7928231
    Abstract: Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: April 19, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: John Gerard Jurcak, Matthieu Barrague, Timothy Alan Gillespy, Michael Louis Edwards, Kwon Yon Musick, Philip Marvin Weintraub, Yan Du, Ramalinga M. Dharanipragada, Ashfaq Ahmad Parkar
  • THIENOPYRAZOLES
    Publication number: 20100056514
    Abstract: Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).
    Type: Application
    Filed: March 26, 2009
    Publication date: March 4, 2010
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: John Gerard JURCAK, Matthieu BARRAGUE, Timothy Alan GILLESPY, Michael Louis EDWARDS, Kwon Yon MUSICK, Philip Marvin WEINTRAUB, Yan DU, Ramalinga M. DHARANIPRAGADA, Ashfaq Ahmad PARKAR
  • Thienopyrazoles
    Patent number: 7518000
    Abstract: Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: April 14, 2009
    Assignee: Aventis Pharmaceuticals, Inc.
    Inventors: John Gerald Jurcak, Matthieu Barrague, Timothy Alan Gillespy, Michael Louis Edwards, Kwon Yon Musick, Phillip Marvin Weintraub, Yan Du, Ramalinga M. Dharanipragada, Ashfaq Ahmed Parkar
  • SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
    Publication number: 20080255350
    Abstract: The present invention relates to a series of substituted aza-indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Application
    Filed: June 17, 2008
    Publication date: October 16, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: John Z. JIANG, Jack Roger KOEHL, Shujaath MEHDI, Neil MOORCROFT, Kwon Yon MUSICK, Philip Marvin WEINTRAUB, Paul Robert EASTWOOD
  • Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
    Patent number: 7405300
    Abstract: The present invention relates to a series of substituted indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: July 29, 2008
    Assignee: Aventis Pharmaveuticals Inc.
    Inventors: John Z. Jiang, Jack Roger Koehl, Shujaath Mehdi, Neil David Moorcroft, Kwon Yon Musick, Philip Marvin Weintraub, Paul Robert Eastwood
  • Indole derivatives as interleukin-4 gene expression inhibitors
    Patent number: 7169925
    Abstract: This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: January 30, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Gregory H. Merriman, Philip M. Weintraub, Jeffrey S. Sabol, Ramalinga M. Dharanipragada, Nicholas J. Hrib, John G. Jurcak, Alexandre Gross, Brian Whiteley, Kwon Yon Musick, Joseph T. Klein
  • Indole derivatives as interleukin -4 gene expression inhibitors
    Publication number: 20040010029
    Abstract: This invention discloses and claims a new class of indole derivatives for use in treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and diseases associated with bacterial, rhinovirus or respiratory syncytial virus (RSV) infections. It has now been found that the compounds of this invention are capable of modulating T helper (Th) cells, Th1/Th2, and thereby capable of inhibiting the transcription of interleukin-4 (IL-4) message, IL-4 release or IL-4 production.
    Type: Application
    Filed: April 23, 2003
    Publication date: January 15, 2004
    Inventors: Gregory H. Merriman, Philip M. Weintraub, Jeffrey S. Sabol, Ramalinga M. Dharanipragada, Nicholas J. Hrib, John G. Jurcak, Alexandre Gross, Brian Whiteley, Kwon Yon Musick, Joseph T. Klein